ALCAM (CD166) expression and serum levels in pancreatic cancer
about
Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell linesCD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cellsCarcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancerPrognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis.Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer.Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer.Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non-small cell lung cancer?Targeting Lung Cancer Stem Cells: Research and Clinical ImpactsA systematic evaluation for the potential translation of CD166-related expression as a cancer biomarker.ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer.Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.
P2860
Q34078502-DD5798CB-E9C1-4990-9F5D-F336C9366759Q34183596-F5BBCF76-4540-4D94-A4A4-725790A91FCAQ34542396-56951D1B-9431-4D7F-A362-4754FC515373Q34936453-840F3504-7544-4A65-A1FA-484403097C65Q35149685-15F8EF65-9744-4F78-8DAB-09634E803B6EQ35152701-B1B875AB-8669-4A49-8348-51F2071848B4Q36680316-6C483C3D-2897-417F-80FE-09F7D7EC937AQ37273157-709C260C-5217-4148-A419-158561A5D95CQ37702349-8158D0B4-42C8-4DCF-B876-02F94CD841FDQ39026693-672A1663-2C75-4675-BF04-CDE700B0FB91Q39321673-3B3D2EA2-737F-4C35-9409-EC970F2B52E2Q39615435-0E628ABA-1187-40DD-9663-1CA9DCC6F7D5Q52571266-7336CB4B-214B-4629-BF01-B4130C40F976Q52665635-7E209AB6-BD89-4ADE-8F50-7C6067395DDC
P2860
ALCAM (CD166) expression and serum levels in pancreatic cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
ALCAM (CD166) expression and serum levels in pancreatic cancer
@ast
ALCAM (CD166) expression and serum levels in pancreatic cancer
@en
type
label
ALCAM (CD166) expression and serum levels in pancreatic cancer
@ast
ALCAM (CD166) expression and serum levels in pancreatic cancer
@en
prefLabel
ALCAM (CD166) expression and serum levels in pancreatic cancer
@ast
ALCAM (CD166) expression and serum levels in pancreatic cancer
@en
P2093
P2860
P1433
P1476
ALCAM (CD166) expression and serum levels in pancreatic cancer
@en
P2093
Andreas H Marx
Florian Gebauer
Hilke Zander
Jakob R Izbicki
Maximilian Bockhorn
Michael Tachezy
Phillip R Stahl
P2860
P304
P356
10.1371/JOURNAL.PONE.0039018
P407
P577
2012-06-20T00:00:00Z